Podcast appearances and mentions of Jonathan Palmer

Earlier this year, Love Jones returned with the album, The Greatest Show on Earth, their first album since 2010, and Ben Daughtrey, Barry Thomas, and Jonathan Palmer discuss their journey to releasing the new album with Nicole Barlow and Ryan Pak on Soundtrack Your Life. They also talk about their start as a band in 1990 and how they ended up in LA, where they would meeting the likes of director John Favreau and actor Vince Vaughn. Favreau and Vaughn who were making an indie-film called Swingers. The band contributed their song "Paid for Lovin'" to the soundtrack but the band was involved with more than just that song. Bassist Barry Thomas was a music consultant on the film, helping pick out songs for the soundtrack, and the band almost ended up in the film itself, since Favreau and Vaughn were such big fans of the band. Ben, Barry, and John share behind the scenes stories about Swingers, they also chat about jamming with producer/composer Jon Brion in the early 90s, and appearing in films like Since You've Been Gone and The Sweetest Thing. For More Information About Love Jones: Website Instagram Their Tonight Show Performance Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Seeing Them Live, Charles sits down with Ben Daughtry and Jonathan Palmer of Love Jones — the Louisville-born, LA-based band that has been crafting their unique blend of lounge, soul, pop, and sharp-witted storytelling for over three decades. The conversation kicks off with a shared love of live music, as both Ben and Jonathan trace their concert-going roots back to the same unlikely starting point: Van Halen. Ben recalls sneaking into a show at 14, way too young to be there, watching a then-unknown Van Halen open for Black Sabbath and feeling like "a bomb going off." Jonathan recounts his own Van Halen baptism at Freedom Hall in Louisville on the Women and Children First Invasion Tour — complete with $7.50 festival seating and his mother taking notes in the stands. From there, the episode becomes a wide-ranging tour through decades of live music obsession. The guys swap stories about Ted Nugent crowd surges, jumping on stage with GWAR in New Orleans, playing congas with Tool at an early Lollapalooza, and watching Rage Against the Machine move 60,000 people. Jonathan shares privileged industry moments — seeing The Rolling Stones at a 600-capacity room in New York alongside Daniel Craig, Rachel Weisz, and Questlove, and catching Nine-Inch Nails at The Troubadour when they felt "too big for the building." The conversation is fueled by genuine enthusiasm, with each story triggering another in a kind of joyful avalanche of rock and roll memory. The second half of the episode turns to the band's own story — from their residency at Largo on Fairfax, where David Bowie once sat quietly in a booth and Tool's crew became regulars, to their unexpected appearance on The Tonight Show with Jimmy Fallon celebrating the 25th anniversary of their debut album Here's to the Losers. Charles and the guys dig into the Cocktail Nation moment of the '90s, the making of their new album The Greatest Show on Earth — written during COVID jam sessions in a Louisville warehouse with crickets chirping and trains passing — and the cinematic, Gil Evans-influenced sound that ties its six expansive tracks together. The episode closes with the band expressing hope to get back on the road, a shout-out to their partnership with Whiskey Thief Distillery, and a tease of possible activity around the 30th anniversary of the film Swingers, on whose soundtrack Love Jones famously appeared. BANDS: Adele, B-52s, Beastie Boys, Big Bad Voodoo Daddy, Black Sabbath, Chicago, Combustible Edison, Devo, Earth Wind & Fire, Fishbone, Foo Fighters, GWAR, James Brown, Led Zeppelin, Love Jones, Metallica, Metric, Molly Hatchet, Morphine, Nine Inch Nails, Oasis, Rage Against the Machine, Red Hot Chili Peppers, Rolling Stones, Sea and Cake, Steely Dan, Supertramp, Ted Nugent, The Cars, The Cocktails, Tool, Tortoise, Van Halen, ZZ Top. VENUES:  Comiskey Park (Chicago), Freedom Hall (Louisville), Largo (Los Angeles), Largo on Fairfax (Los Angeles), Lollapalooza, Metro (Chicago), Racket (New York City), Rose Bowl (Pasadena), Soldier Field (Chicago), The Troubadour (Los Angeles). PATREON:https://www.patreon.com/SeeingThemLivePlease help us defer the cost of producing this podcast by making a donation on Patreon.WEBSITE - BECOME A GUEST:https://seeingthemlive.com/Visit the Seeing Them Live website and click on the link to fill out a form so we can consider you as a guest on the show.INSTAGRAM:https://www.instagram.com/seeingthemlive/FACEBOOK:https://www.facebook.com/profile.php?id=61550090670708

Sunday Message from guest speaker, Pastor Jonathan Palmer from Summit Creek Church.

A 57-year-old woman is enjoying retirement in the quiet Worcestershire countryside just days before Christmas 2009. After more than two decades of marriage, Melinda Palmer and her husband Jonathan have recently moved into an isolated detached house surrounded by fields and woodland in the tiny village of Wadborough. Friends and neighbours describe them as a devoted couple beginning a peaceful new chapter together. But on the evening of December 22nd, Jonathan Palmer dials 999 claiming he has returned home to find his wife brutally murdered at the bottom of the stairs after an apparent burglary gone wrong.Police arriving at Windy Ridge discover a disturbing scene. Drawers and cupboards have been pulled open, blood stains are in the hallway, and Melinda has suffered catastrophic head injuries. Yet almost immediately, detectives begin to suspect something is very wrong with Jonathan's story. Valuable jewellery has been left untouched, forensic evidence suggests the scene has been staged, and investigators soon uncover a secret life hidden behind the image of a loving husband.In this episode of British Murders with Stuart Blues, we examine the murder of Melinda Palmer and the web of lies that unravelled after her death. From Melinda's successful career with British Gas and the couple's move to rural Worcestershire, to Jonathan's secret mobile phone, online affairs, fake identities, and bizarre double life, this is a case built on deception, betrayal and greed. We explore the police investigation, the forensic evidence that pointed towards Jonathan, the staged burglary theory, the suspicious motorway journey made after the killing, and the chilling behaviour of a man attempting to pose as a grieving husband while covering his tracks.We also break down the 2010 murder trial at Worcester Crown Court, where prosecutors alleged Melinda discovered her husband's affairs shortly before he launched a violent attack that left her dead inside the home they had planned to grow old together in. From bloodstained fingerprints and missing clothing, to secret text messages, hidden relationships and the devastating impact on Melinda's family, this is a heartbreaking true crime story about a woman murdered by the person she trusted most, and the lies that finally caught up with him.Exclusive content:Patreon - Ad Free, Early Access, Exclusive EpisodesFollow the show:British Murders with Stuart BluesDisclaimer:The case discussed in this podcast episode is real and represents the worst day in many people's lives. I aim to cover such stories with a victim-focused approach, using information from publicly available sources. While I strive for accuracy, some details may vary depending on the sources used. You can find the sources for each episode on my website. Due to the nature of the content, listener discretion is advised. Thank you for your understanding and support. Hosted on Acast. See acast.com/privacy for more information.

“It’s crazy to think that that would be the expectation in cancer care, yet we expect that of families in autism,” says Neil Hattangadi, CEO and co-founder of Cortica. Hattangadi joins Bloomberg Intelligence analyst Jonathan Palmer to explain why autism care remains so fragmented and how Cortica is trying to replace siloed services with a coordinated whole-child model. They discuss why applied behavior analysis (ABA) should be one tool, not the whole answer, how Cortica integrates medical and behavioral care, and why better coordination could ease the burden on families while improving outcomes.See omnystudio.com/listener for privacy information.

"We are a group of analysts working in the greater context of the analytic world, but as a group, we have a profound analytic group process that's evolved and in profoundly successful ways - we've become a group that contains one another, and deals with great difficulties. Mel has given a taste of where we go to an emotional authenticity that's very compelling… Somehow, we've gotten to a place where nobody seems to be hungry in the group. You're not hungry for affirmation or support, so that there isn't a sense that people are waiting to say something smart or do something smart or make a brilliant interpretation, and there's enough resources left over that the tendency is so powerful to look to enhance somebody else's sense of aliveness and creativity." J.P.   I feel very lucky in this group, because I received a gem of a gift that was unexpected. We were going along as a group in this wonderful way. I would look forward to speaking with everybody every four weeks. We got a lot of work done. We also became part of each other's lives in our own way. However, there was always reality around us that we had to cope with. And suddenly, last year, I had a catastrophic medical event in which I had routine surgery that went extremely well, and when I went to leave the hospital, I had a cardiac arrest, and then basically six weeks of ICU care, and lived because I was in a hospital. But it is this group that then took on even more of a meaning for me, because I felt the presence of everyone near me in this group always, and it did give me the sense that the group had also morphed into its own living, breathing entity that really kind of enveloped me at a very painful time. I realized we could go back and forth as a group, actually quite easily, between clinical work, psychoanalytic thinking, and the harsh realities of time, illness, whatever that would intrude or were surrounding us as a group. To me, this was kind of a miracle of a gift. It's been life-saving, really life-saving." P.W.   "Developing a sense of one another in how not only we talk, but who we are. That friends are people I feel I can be fully open with and not have to worry about it, to feel free and even when I say things that I might question or regret or feel self- conscious or embarrassed about with friends -  it's held, and I feel this has happened in this group, that there is a way in which we very tenderly hold one another, and there's something about that space, perhaps it's an analytic space. I feel we do it with our patients, but I feel with our peers. It's a very precious thing indeed." M.M.   Episode Description: This episode of the podcast takes a step back from our usual focus on how an analytic mindset can improve the lives of those in our care - either on or off the couch. Today, we consider how we can and do care for ourselves and each other. We are a group of six analysts who have been meeting regularly for 10 years. We evolved from a thirty-year group originally devoted to the study of analytic writing. We now meet to share our lives and our work in what Peggy Warren calls "a living and breathing entity."  We discuss "what we need as analysts to go on with this work", how time and illness has changed us as a group, how we feel we can share ourselves without inhibiting self-consciousness, and how what Mel Bornstein calls a 'love of life' can serve as an organizing spirit for what we do. We take up how the group is embedded into a creative process, individually and together. Jon Palmer closes our meeting by noting "there's a lot of love in this room - a necessary condition for us all to grow."   Our Guests: Stephen Bernstein, Jonathan Palmer, and Peggy Warren are on the faculty of the Boston Psychoanalytic Society and Institute. Melvin Bornstein is on the faculty of the Michigan Psychoanalytic Institute. Mark Moore is on the faculty of the Psychoanalytic Center of Philadelphia, where Harvey Schwartz is also on the faculty, and of the Psychoanalytic Association of New York. Watercolor by Jonathan Palmer  

“We cannot fix a food problem with drugs,” says Sami Inkinen, CEO and co-founder of Virta Health. Inkinen joins Bloomberg Intelligence analyst Jonathan Palmer to explain why Virta is betting that reversing metabolic disease can become one of the most important cost and outcomes stories in health care. He details how the company combines nutrition therapy, intensive telemedicine and AI to deliver sustained weight loss, diabetes reversal and significant savings for employers and health plans. The conversation also explores Virta’s long commercialization path, its growing traction in the B2B market and why Inkinen believes disease reversal is a far bigger opportunity than simply managing chronic illness more efficiently.See omnystudio.com/listener for privacy information.

“We’re never moving fast enough,” says Bob Segert, CEO of Athenahealth. Segert joins Bloomberg Intelligence analyst Jonathan Palmer to explain the strategic reset that reshaped Athenahealth: cutting losing bets, doubling down on ambulatory care and building around its cloud-native athenaOne platform to drive operating leverage. The conversation covers Athena’s aggressive AI pivot, its open-platform strategy and why speed, product discipline and better physician economics will determine the next market winners.See omnystudio.com/listener for privacy information.

“I think 2026 is the year of fundamental, agentic transformation of the workflow.” Abridge co-founder and CTO Zack Lipton joins Bloomberg Intelligence analyst Jonathan Palmer to share how the company grew from a research-heavy idea into one of health care’s breakout AI leaders. Lipton breaks down the limits of point solutions, the complexity of evaluating generative AI in medicine, and why he sees the future not as a better digital scribe alone, but as a unified platform that can guide documentation, billing and care decisions in real time.See omnystudio.com/listener for privacy information.

“In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,” says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire’s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women’s health, the evolving AI landscape and the personal values — integrity, work ethic and mission — that shape how she invests and leads.See omnystudio.com/listener for privacy information.

“I wake up every day wanting to make health care better,” says Halle Tecco, founder of Rock Health and author of Massively Better Healthcare. Tecco joins Bloomberg Intelligence analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast to reflect on digital health’s evolution — from her early days at Apple’s App Store to building one of the sector’s first venture funds. She explains why Covid reset adoption curves, how hospitals became leading tech buyers and why aligning “margin and mission” now shapes her investment lens. Tecco also shares lessons from backing a laundry list of well-known startups, teaching at Columbia and Harvard, and why she wrote a book to empower the next wave of innovators.See omnystudio.com/listener for privacy information.

“Health care creates friction everywhere — copays, approvals, pre-authorizations — and none of that matters when someone you love needs help right now,” says Glen Tullman, CEO of Transcarent, in his return to the Vanguards of Health Care podcast to explain why speed, access and simplicity are existential issues in US health care. In a wide-ranging conversation with Bloomberg Intelligence analyst Jonathan Palmer, Tullman outlines Transcarent’s vision for delivering 24/7 care through an AI-first, mobile-native platform. He discusses why legacy navigation models fail consumers, how the Accolade acquisition accelerates Transcarent’s strategy and why WayFinding reframes benefits, clinical guidance and care delivery into a single real-time experience designed around human urgency — not the administrative process.See omnystudio.com/listener for privacy information.

“Revenue cycle is really about solving two problems: generating an accurate receipt and then jumping through the fifty hoops to get paid.” says Dr. Michael Gao, CEO of Smarter Technologies. In this episode of Vanguards of Health Care, Gao joins Bloomberg Intelligence analyst Jonathan Palmer to explain how AI is transforming hospital revenue cycle management (RCM). He walks through Smarter’s approach to clinical intelligence and automation, why AI works best as a first pass with human supervision, and how smarter workflows can lift margins for hospitals operating on razor-thin economics. The conversation also explores Smarter’s formation with New Mountain Capital and Gao’s mission to reduce the trillion-dollar burden of health care administration.See omnystudio.com/listener for privacy information.

“Our mission is to create both strategic and financial returns by backing scalable technologies that can transform how biopharma operates.” Bill Taranto, president and general partner of the Merck Global Health Innovation Fund, joins Bloomberg Intelligence analyst Jonathan Palmer to break down how Merck’s $600 million evergreen venture arm invests at the intersection of biotech and health tech. Taranto explains why GHI focuses on pharma services across drug development, supply chain, patient access and real-world evidence, how ecosystem investing and private equity drive scale, and why AI and data are reshaping the future of pharma operations.See omnystudio.com/listener for privacy information.

“AI agents are at the knee of the curve in terms of where things are headed,” says John Beadle, Aegis Ventures co-founder and managing partner. In this episode of the Vanguards of Health Care podcast, Beadle joins Bloomberg Intelligence analyst Jonathan Palmer to unpack Aegis’s thesis-driven approach to founding AI-native health-care companies. He details how its 14-system consortium sources problems directly from operators, why automation is the biggest near-term value driver and how ventures like Ascertain have emerged from that model. Beadle also discusses the evolving venture market, the rise of agentic AI and why his personal experiences, shaped by his mother’s medical journey, fuel his mission to make the system more accessible and equitable.See omnystudio.com/listener for privacy information.

“It’s hard to overemphasize how broken we are in how we care for older adults.” says Seth Sternberg, CEO of Honor. Sternberg joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how Honor’s AI-driven logistics and the Home Instead network tackle the hardest problem in home care: scaling quality. In this episode of the Vanguards of Health Care podcast they dive into matching the right caregiver to the right client, why stability is the No. 1 caregiver need, franchise advantages, and making private‑pay care more affordable for the middle class plus how quality metrics and “defect rates” power growth.See omnystudio.com/listener for privacy information.

What's your most loved and least favourite song on Everything But The Girl's debut 1984 album, Eden? Jim picked this purdy teen fave so we got to talk about our young twee/jazzy leanings. Quietest album we've ever ranked? Shhh. Maybe. Love Jones singer Jonathan Palmer swings in with his thoughts and opinions!   Available at WeWillRankYouPod.com, Apple, Spotify and everywhere you get podcasts but...there.  Please tell us how YOU would rank tonight's tunes on Instagram, Facebook and Threads  @wewillrankyoupod !FILE UNDER/SPOILERS:Another Bridge, Aztec Camera, Bittersweet, Blanco y Negro, Simon Booth, bossa nova, Crabwalk (Instrumental), Joao Bosco De Oliveira, the Doors, The Dustbowl, Each and Every One, Echo and the Bunnymen, Eden, England, Even So, Everything But The Girl, Fascination, Jane Fox, Frost and Fire, Hammond organ, Happy Mondays, Charles Hayward, Hull, I Must Confess, indie pop, jazz, Pete King, Love Jones, Marine Girls, Chucho Merchán, Robin Millar, Missing, Nigel Nash, new wave, Night and Day, Jonathan Palmer, Dick Pearce, Mike Pela, Sade, samba, saxophone, the Smiths, Soft Touch, The Spice of Life, the Style Council, Tender Blue, there's a, Tracey Thorn, Ben Watt, Paul Weller, 1984. US: http://www.WeWillRankYouPod.com wewillrankyoupod@gmail.comNEW! Host tips: Venmo @wewillrankyoupodhttp://www.facebook.com/WeWillRankYouPodhttp://www.instagram.com/WeWillRankYouPodhttps://www.threads.net/@WeWillRankYouPodhttp://www.YerDoinGreat.com (Adam's music page)https://open.spotify.com/user/dancecarbuzz (Dan's playlists)

“Our vision as a company is to help eradicate cancer with tests that prevent it, detect it earlier and guide treatment,” says Kevin Conroy, CEO of Exact Sciences. He joins Bloomberg Intelligence analyst Jonathan Palmer on the Vanguards of Health Care podcast to trace Exact’s journey into a cancer-diagnostics leader. From Cologuard’s initial rise to its recently launched Cologuard Plus test, the debut of Cancerguard and expansion into minimal-residual disease (MRD) testing, Conroy shares how science, technology and culture underpin the company’s next decade.See omnystudio.com/listener for privacy information.

“American medicine is the best in the world, but the American health-care system is not,” Akasa CEO Malinka Walaliyadde says. In this Vanguards of Health Care episode, Walaliyadde joins Bloomberg Intelligence analyst Jonathan Palmer to explore how Akasa is tackling the chaos of revenue-cycle management with AI. He explains why America’s overlapping payment models create inefficiency, how large-language models read massive patient records in minutes and why custom models built for each health system outperform off-the-shelf AI. They also discuss Akasa’s performance-based business model and the path toward real-time payer-provider communication, as well as the role that grit and conviction play in building a transformative company.See omnystudio.com/listener for privacy information.

“We don’t just invest — we bring knowledge, network and opportunity,” says Edward De Nor, partner at GHO Capital, as he joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how the firm identifies and scales mid-market health-care companies that enable better, faster, more accessible care. He explains GHO’s investment thesis, its “picks and shovels” strategy and how innovation, not disruption, fuels compounding growth. The two explore case studies like BioAgilytix, the role of AI as an enabler and why boardrooms should obsess over the customer, not just the P&L.See omnystudio.com/listener for privacy information.

“We don’t have to do every great deal, but every deal we do has to be great,” says Payal Agrawal Divakaran, partner at .406 Ventures. In this Vanguards of Health Care episode, she joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how .406 backs early-stage startups at the intersection of health care, tech and AI. They dive into the firm’s thesis-driven investing, why care delivery must be reimagined for complex populations and what Epic’s priorities mean for hospital-facing AI startups. Plus, the origins of the firm’s baseball-inspired name and why being mission-driven is non-negotiable for its founders.See omnystudio.com/listener for privacy information.

“We truly see ourselves as an operating system for payers,” says David Pierre, CEO of Machinify. Pierre joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how Machinify is using AI to reimagine payment integrity, turning a manual process into a proactive, tech-enabled platform. They discuss Machinify’s formation from four legacy and technology companies, its AI-first claims strategy and how the team is driving real-time adjudication and measurable cost savings. Pierre also shares what he’s learned from Cerner and Signify, and where Machinify is heading next.See omnystudio.com/listener for privacy information.

“The PBM space has been worse than some criminal enterprises — they are stealing money from employers and employees,” says Jordan Feldman, CEO and co-founder of Rightway Healthcare. Feldman joins Bloomberg Intelligence analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast to unpack how Rightway is building a member-first pharmacy benefit manager (PBM) — one without rebates, gimmicks or hidden margins. They dive into Rightway’s origin story, how its care-navigation platform grew to 3.5 million members, and why a transparent, clinically-grounded PBM is the antidote for industry dysfunction. Feldman also shares thoughts on GLP-1 drugs, AI and what it means to be the so-called N-of-one alternative to the Big 3 PBM’s monopoly.See omnystudio.com/listener for privacy information.

“Mental health care is still living in the mid-20th century,” says Mark Frank, CEO and cofounder of SonderMind. Frank joins Bloomberg Intelligence analyst Jonathan Palmer to break down how SonderMind is reimagining behavioral health from its antiquated roots by layering technology and data, and while seamlessly integrating digital tools into therapy. The pair also discuss the company’s pandemic pivot to virtual care, its move toward risk-based contracting and the role AI will play in transforming behavioral care from a subjective art into a data-driven science — which Frank sees as the key enabler for mental health to be treated with the same precision as physical health.See omnystudio.com/listener for privacy information.

“We want to bring health care to a place where claims are processed in real-time, like checking out on Amazon,” says Stephen Krupa, CEO of HealthEdge. Krupa joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how HealthEdge’s core platform powers claims processing for more than 110 million people. He shares how legacy infrastructure still dominates (with 60% of health plans still relying on decades-old technology), why automation and gen AI will drive touchless transactions and how payer platforms must evolve to support member-centric care. Krupa also reflects on HealthEdge’s journey from startup to its transformation under Blackstone, and what the next chapter might look like with Bain Capital.See omnystudio.com/listener for privacy information.

“We exist to solve prior authorization so patients can get the care they deserve,” says Dr. Jeremy Friese, founder and CEO of Humata Health. Friese joins Bloomberg Intelligence health-care analyst Jonathan Palmer to discuss how Humata’s AI-driven technology is transforming one of health care’s most notorious administrative headaches. They cover how Humata connects deeply into medical records, helps both providers and payers streamline approvals and is expanding into specialty pharmacy. Friese also shares his journey from Mayo Clinic radiologist to serial entrepreneur — and why he believes solving back-office burdens can unlock better patient care.See omnystudio.com/listener for privacy information.

“Health care is finally ready to operate at information speed,” says Jonathan Bush, co-founder and CEO of Zus Health. Bush joins Bloomberg Intelligence analyst Jonathan Palmer to explain why he believes health care is poised for a digital transformation. He unpacks how Zus uses AI and FHIR-native tools to pull patient data from fragmented sources, clean it and serve it back to providers in actionable form. From uncovering the “fire in the trash” to helping doctors identify high-risk patients before costs spike, Bush shares what it means to be a modern health-tech platform and why he came out of retirement to build it. They also discuss the early customers driving growth, lessons from Athenahealth and why gross margin, not buzz, is the new benchmark for digital health.See omnystudio.com/listener for privacy information.

Newly appointed Ulster County historian Eddie Moran discusses the role of a municipal historian and emphasizes the importance of presenting a complete and accurate history that includes all groups, with one such focus on the indigenous Lenape people. Moran, a SUNY New Paltz graduate and descendant of the region's Huguenot and Dutch colonists, shares his experiences working with various local organizations to expand the historical narrative. The episode also features a tour of the Ulster County Hall of Records led by archivist Jonathan Palmer, exploring the extensive archival collections and discussing the preservation and digitization efforts.00:00 Introduction and Context00:27 Meet Eddie Moran: Ulster County's New Historian01:38 Eddie's Journey and Passion for History06:55 The Role and Responsibilities of a County Historian10:54 Challenges and Goals in Historical Narratives16:50 Exploring the Ulster County Hall of Records19:34 Preserving History: Techniques and Challenges27:38 Significant Historical Documents and Their Stories38:55 Conclusion and Credits---Audio recording by Izzy SchuylerBehind-the-scenes video by Ruby Zuckerman

On this episode of the Astonishing Healthcare podcast, Bloomberg Intelligence's Jonathan Palmer (Sr. Equity Analyst & Team Lead, Healthcare) joins us in the studio for a discussion about the work his team does and the evolving landscape of health tech. Palmer notes interest in Hinge Health's potential IPO and how the market's receptivity to tech-enabled healthcare companies has improved recently. While these companies face pressure to demonstrate profitability amid evolving market dynamics, there's optimism about innovation on several fronts. He also explains the impact of health policy uncertainty and questions about what the FDA, FTC, DOJ, and CMS will do on investors' ability to place bets: ambiguity causes market hesitation, and investors gravitate toward safe havens.The discussion also covers areas of focus for 2025, including:Palmer's favorite Vanguards of Healthcare podcast episodes and why he enjoys speaking with private company CEOs and venture capital leadersBiopharma Innovation, including GLP-1s, oncology readoutsMedTech Advancements like surgical robotics, cardioablation, and evolving insulin delivery systemsCapital Spending Concerns as US providers and China's healthcare sector are under scrutinyHealthcare Services: online pharmacy growth and Medicare Advantage trendsReference Materials Courtesy of Bloomberg IntelligenceNorth America Managed-Care Policy OutlookN.A. Health-Care Tech, Distribution: 2025 OutlookRelated ContentVanguards of Health Care: How Capital Rx is Fixing America's Broken Drug PricingAH057 - How First-Movers are Taking Control of their Health Plans in 2025, with Jeff HoganAH047 - What Project 2025, RFK Jr., and Dr. Oz Could Mean for the Business of Healthcare Under TrumpAH046 - What's Hot In and Around the Pharmacy Supply Chain, with RSM's Tom EveganFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

“We decided to come to the table with a health-plan model that enables what we like to call radical affordability,” said Ashok Subramanian, CEO and co-founder of Centivo, in this episode of the Vanguards of Health Care podcast. Subramanian joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how Centivo’s approach to self-funded employer plans focuses on reducing costs without sacrificing quality. By leveraging direct-provider partnerships and emphasizing primary care, the company aims to keep 75% of members’ out-of-pocket costs below $200 per year. The conversation covers how Centivo differentiates itself from traditional insurers, its expansion into new markets, and how it helps employers navigate high-cost treatments like GLP-1 drugs while maintaining sustainable benefits for workers. See omnystudio.com/listener for privacy information.

"The mission of Capital Rx is to give our country the infrastructure we need for the healthcare we deserve." AJ Loiacono, CEO and co-founder of Capital Rx, shares with Bloomberg Intelligence analyst Jonathan Palmer how his company is reshaping the pharmacy benefit management (PBM) industry by eliminating hidden costs and conflicts of interest. He explains how traditional PBMs profit from inflated drug prices, creating a system where the most expensive drugs are preferred over more affordable alternatives. Capital Rx aims to disrupt this model by using technology to reduce administrative costs and promote transparency. The discussion also covers regulatory reform and how AI-driven claims processing, with a unified approach to medical and pharmacy benefits, could unlock massive cost savings.See omnystudio.com/listener for privacy information.

"The conversation is the treatment in behavioral health, but clinicians spend too much time documenting instead of caring,” says Alon Joffe, CEO and cofounder of Eleos Health, in this episode of the Vanguards of Health Care podcast. Joffe joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how Eleos is revolutionizing behavioral health care with AI-driven solutions that reduce administrative burdens by 80% while enhancing clinical outcomes. He shares how Eleos leverages multimodal AI to automate documentation and improve decision-making, enabling clinicians to provide better care. The conversation explores Eleos’ expansion into psychiatry, substance-use treatment and long-term care, as well as its vision to become the AI-native operating system for compassionate care.See omnystudio.com/listener for privacy information.

“There’s no digital feedback loop in health care, you have it in Tesla, in Netflix, in Amazon — but not in the industry that impacts every life,” Terry Myerson, CEO of Truveta, explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Myerson joins BI analyst Jonathan Palmer to discuss Truveta’s mission to aggregate and analyze health data across 30 major US health systems, covering one-third of Americans. He details the company’s work in regulatory-grade safety and efficacy research, the launch of the Truveta Genome Project with partners like Regeneron and Illumina, and the power of AI-driven insights to accelerate medical discovery. The conversation explores Truveta’s efforts to address data fragmentation, privacy, and interoperability challenges that must be solved to revolutionize patient care and life sciences.See omnystudio.com/listener for privacy information.

“We sit at the intersection of those large-scale incumbents and entrepreneurs, to help bridge the gap,” Josh Flum, managing partner at LRVHealth, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Flum joins BI analyst Jonathan Palmer to discuss how LRV’s purpose-built model looks to identify and capitalize on durable long-term trends emerging in health care. With only strategic investors as limited partners, LRV believes it has a differentiated perspective on where the market is headed. The conversation delves into the evolution of pharmacy services and why it’s important to build high-performing teams. The exchange wraps up with the state of the IPO market and key takeaways from the JPMorgan Healthcare conference.See omnystudio.com/listener for privacy information.

“The average benefit value for supplemental benefits was about $155 per member. Five years later, it was over $1,500 per member,” Robby Knight, CEO and cofounder of Soda Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Knight joins BI analyst Jonathan Palmer for a wide-ranging discussion on the rapid evolution of the supplemental-benefits market and the challenges Soda faced in building in a new platform that creates incentives for members, retail partners and plan sponsors. The conversation touches on why Medicare Advantage plans were in an arms race to offer unsustainable benefits, why the correction is an opportunity for the company and how the future will bring optimized benefits at the member level.See omnystudio.com/listener for privacy information.

“Our mission is to make cancer less deadly through widely accessible next-generation early-detection blood tests.” Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Tousi joins BI analyst Jonathan Palmer to discuss the company's fragment-based liquid biopsy technology and the immense opportunity to save lives through early cancer detection. Starting with lung cancer via its FirstLook test, Delfi expects to expand more broadly into other cancer types and applications like monitoring with a focus on access and affordability. The conversation touches on the company's core values and the large opportunity set afforded by recent funding rounds.See omnystudio.com/listener for privacy information.

"A number of art schools in the early 60s said: “Clearly, it is the relationship of the painter to the medium that is the essence of painting - the painter must be emotionally present, and this is what we should instill in our students.” So they started to take away traditional training in art schools of representational drawing, of color theory, of figurative drawing, and what they ended up with was a generation of artists who were passionately throwing paint at canvases but unable to make art. The relationship between the fundamentals and intuition is very complicated. Nobody seemed to make the point that the great abstract expressionists  were all trained for decades in traditional art schools. That's what they came out of, and we see this in our analytic colleagues. Many of them are writing wonderfully at the moment, but they were trained as Kleinians or trained as ego psychologists, and they have that in their bone marrow. The kind of representational work with Apple [painting of his dog] that I am talking about when I say: I draw and I draw and I draw until I can put that aside, in analytic work I go to something basic in my training. For me it happens to be something that's close to Paul Gray, it's not where I'm going to stop, but I can use Paul Gray because that's what I was trained in - I will look for transference, I'll look for defense, I'll look for resistance and I'll go back and look for the derivatives of certain affects that are enacted in the relationship. I go over it and over it until I can relinquish it like I did with the painting of Apple, and then the intuitive comes in, but the intuitive is the reward at the end of decades of hard work."   Episode Description: We begin with Jon's mother's encouragement to paint by finding the bird's vitality through "becoming the bird." This leads us to consider the relationship between intuitive seeing and the "images which I might desire to produce." We discuss his notion of the aesthetic matrix which applies both to the analytic encounter as it does to the painter's relationship to his creative process. Jon shares with us his conviction that basic technique, whether artistic or analytic, must first become part of one's inner make-up before intuition can enlighten an obscure moment. He walks us through his creative process in the face of a blank canvas on the wall in front of him. He discusses the different uses of watercolor and oil paint and how their unique properties parallel his spontaneous engagement at various periods of an analysis. He presents a clinical encounter and how he was able to unpack a countertransference impasse through working on a painting. He closes with sharing an experience he had in his native South Africa which leads him to feel that "it's a blessing to be able to work in America."   Linked Paper and Websites: The Aesthetic Matrix: A Conversation Between a Painter and a Psychoanalyst  

“When I looked at the industry, I saw a real opportunity set to build a best-in-class sector-focused fund,” Lynne Chou O'Keefe, founder and managing partner of Define Ventures, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. O'Keefe joins BI analyst Jonathan Palmer for a deep discussion into Define's unique approach to health-care investing, emphasizing the importance of both health-care and tech expertise. The two discuss the major trends shaping health care, including technology, consumerization and the evolution of the value chain. The podcast concludes with insights into the state of the market, including valuations, IPOs and potential consolidation.See omnystudio.com/listener for privacy information.

On this week's My Week In Cars podcast our hosts Matt Prior and Steve Cropley are joined live at the Royal Automobile Club in London by Jonathan Palmer, CEO of MotoSport Vision. Hosted on Acast. See acast.com/privacy for more information.

“Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company's recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.See omnystudio.com/listener for privacy information.

Listen in as Jonathan Palmer, CEO of Autometrix and member of the ATA Board of Directors, interviews Ethan Halpern, President of American Awning & Blind Co., Daniel Cuppels, Operations Manager at Blithe Defense Industrial Covers, and Alberto Ramirez, CEO of Just 4U Custom Canvas, Inc. They will discuss what makes their textile businesses unique and different on the West Coast. They will also discuss how ATA has helped them become more knowledgeable in the industry with online resources like the member directory and holding Expo each year so they can meet and network with individuals and companies.

“Tempus is focused on the idea of bringing technology, and in particular artificial intelligence, to diagnostics by essentially combining a molecular result and then connecting that to clinical data for that patient.” Eric Lefkofsky, Founder and CEO of Tempus AI, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Lefkofsky joins BI analyst Jonathan Palmer for a discussion on how Tempus built a multipurpose platform that generates unique insights not only for treating patients but also in drug discovery and speeding recruitment for clinical trials. The two cover how oncology is just the first beachhead, why it's still early days for the company's data business and the future of using algorithms in treatment.See omnystudio.com/listener for privacy information.

 "If all goes well, Heartbeat Health will be a household name for the first referral from primary care for cardiology. It'll be easier than everyone else out there and less expensive than other referrals." Dr. Jeff Wessler, CEO and Founder of Heartbeat Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wessler joins BI analyst Jonathan Palmer to discuss the genesis of Heartbeat's decentralized cardiology practice, how the company iterated from a brick and mortar clinic to a virtual platform to speed access, and why keeping patient care at the center has improved outcomes.  See omnystudio.com/listener for privacy information.

 "We analyze vocal biomarkers in near real time and correlate that to a clinical diagnosis and create an algorithm that then can independently identify a range of different diseases in the human voice during conversation," Henry O'Connell, CEO and Co-founder of Canary Speech, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. O'Connell joins BI analyst Jonathan Palmer to discuss the company's origins, its unique approach to vocal analysis using over 2,500 speech features and its commitment to clinical validation through partnerships with leading healthcare institutions. The conversation touches on Canary's foundational team, extensive patent portfolio and platform approach that enables the development of models for a wide range of diseases. See omnystudio.com/listener for privacy information.

“We're staking the company on personalization: If you can make the health-care experience more personal to the individual, they'll be more likely to engage around their health care and take the proper actions to get better outcomes,” Chris Michalak, CEO of Personify Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Michalak joins BI analyst Jonathan Palmer to discuss the merger of Virgin Pulse and HealthComp, the company's AI-driven personalization engine and the value proposition for employers. The conversation also covers Personify's approach to consolidation in health care, the role of navigation and the impact of GLP-1 drugs on the market.See omnystudio.com/listener for privacy information.

“We're here to lower the cost of prescription drugs for every American,” Mark Thierer, CEO of Waltz Health explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Thierer joins BI senior health care analyst Jonathan Palmer to discuss Waltz's Marketplace Search solutions for pharmacies and payers and why the upcoming launch of its Intelligent Specialty Engine is a game changer. He also shares his insights into the latest trends affecting the PBM industry.See omnystudio.com/listener for privacy information.

“We are driving the market to exome and genome testing with a goal of making multigene panels be a thing of the past” Katherine Stueland, CEO of GeneDx, tells Bloomberg Intelligence's analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast. They discuss GeneDx's 80% market share in exome sequencing, the evolution of the genetic testing market and why the company's core mission is delivering clinically-actionable results in rare diseases.  See omnystudio.com/listener for privacy information.

Hair testing ~ How to really get to know your hair Dr Jonathan Palmer has a PHD from Imperial College and works in Biotechnology. He has worked for cancer research and blood testing, and has now founded Hair Knowhow.Dr Palmer describes himself as an experimentalist, who has been passionate about science since he got his first telescope at 7 years old.He uses tests designed for product development, producing results for people who want to know about their hair health. These hair tests produce impartial, data led diagnoses, which Jonathan describes as a branch of personal medicine.Hair knowhow can test the hair in depth biochemically, inside & out. They can measure protein loss, porosity, lustre and the extent of physical or chemical damage. Their aim is to help people be able to make choices on products & practices that can better look after their hair.They can work with trichologists to enable them to provide a fully comprehensive hair analysis.Connect With Dr Palmer:InstagramWebsite Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

When Wegovy was approved in 2021, patients began inquiring about whether Ro could build a product that would give them the “Ro experience” in weight loss: The company went to work at the end of 2021, spent all of 2022 building it, launched in 2023 and is now scaling up, CEO and co-founder Zachariah Reitano explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Reitano sat down with BI analyst Jonathan Palmer to discuss how the Ro platform is uniquely positioned to scale in chronic care, the drivers of unprecedented demand for GLP-1 drugs, how taking friction out of the patient experience led to early success and why he's trying to recreate his physician father with technology.See omnystudio.com/listener for privacy information.

He didn't come from a racing family. He followed in the footsteps of his father and qualified as a doctor. How Jonathan Palmer ended up driving in Formula 1 is an intriguing tale of passion for racing, intuition and plenty of graft. Palmer initially competed in Formula Ford but after qualifying as a doctor, he decided to focus on racing professionally. He became British Formula 3 champion in 1981 and European Formula 3 champion in 1983. That year, Williams gave him his F1 debut at the European Grand Prix. He would go on to race for RAM, Zakspeed and Tyrrell over the next six years – scoring 14 championship points along the way. Palmer takes Tom Clarkson through his unique journey from studying medicine to competing in Formula 1. He reflects on some memorable drives in Monaco and we hear wonderful insight into what it was like working with Ayrton Senna as a test driver for McLaren in 1990. Palmer, whose son Jolyon also raced in F1 for Renault in 2016 and 2017, became part of the BBC's Formula 1 coverage after retiring. He recalls working the day Senna lost his life at Imola in May 1994. Follow, rate and review F1 Beyond The Grid and share this episode using #F1BeyondTheGrid.